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Abstract: Cardiovascular diseases (CVD) including coronary artery disease (CAD) and ischemic
heart disease (IHD) are the main cause of mortality in industrialized countries. Although it is well
known that there is a difference in the risk of these diseases in women and men, current therapy
does not consider the sexual dimorphism; i.e., differences in anatomical structures and metabolism
of tissues. Here, we discuss how genetic, epigenetic, hormonal, cellular or molecular factors may
explain the different CVD risk, especially in high-risk groups such as women with diabetes. We
analyze whether sex may modify the effects of diabetes at risk of CAD. Finally, we discuss current
diagnostic techniques in the evaluation of CAD and IHD in diabetic women.
Keywords: coronary artery disease; gender; sex; women; diabetes; cell signaling; biomarkers
1. Introduction
Cardiovascular diseases (CVD), such as coronary artery disease (CAD), coronary heart disease
(CHD, including myocardial infarction) and ischemic heart disease (IHD), are the main cause of
mortality in the European Union, accounting for nearly 45% of all deaths in Europe and 37% of all
deaths in the European Union in 2017 [1]. Cardiovascular risk in people with diabetes mellitus (DM) is
significantly higher than those without the disease. However, increasing evidence indicates that risk of
CAD and IHD is different in women and men. Indeed, the relative risk of fatal IHD associated with
diabetes is 50% higher in women than men [2]. Furthermore, the diagnosis of CAD is more challenging
in women, as traditional diagnostic tests are less sensitive and specific in female patients, showing
a lower prevalence of obstructive CAD, a greater burden of symptoms, and a high atherosclerotic
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burden [3]. Current treatments are limited, as the best available therapy reduces the cardiovascular
risk by only 25–30%, and remains virtually ineffective in reducing the excess risk associated with
diabetes. In addition, the propensity to treat is significantly lower for women than for men, especially
at a younger age. In fact, most cardiovascular treatments, including antiplatelet agents, beta-blockers,
lipid-lowering agents or coronary angioplasty were significantly less frequent in women in a recent
study involving patients aged 35 to 54 years [4]. Furthermore, current therapeutic approaches do not
consider sexual dimorphism between women and men, including differences in anatomical structures
(i.e., size and body composition, as well as the different nature of adipose tissue [5]). In line with
this assumption, it has recently been shown that sexual dimorphism influences the expression of
genes related to the mitochondria of human cells in the body, including cardiovascular cells [6].
Therefore, sexual dimorphism may result in a different pharmacokinetics of the currently used drugs
for the treatment of CVD, as well as a different response to them in terms of gene expression and
epigenetic differences.
Here, we discuss how genetic, epigenetic, hormonal, cellular or molecular factors may explain
the higher risk for CAD in women, especially in high-risk groups such as women with diabetes. We
will analyze how sex modulates the effects of diabetes on CAD and IHD. Finally, we discuss the
available evidence on the role of current diagnostic techniques in the evaluation of CAD and IHD in
diabetic women.
2. Coronary Artery Disease and Ischemic Heart Disease in Diabetic Women: Defining the
Problem
The cardiovascular risk in people with diabetes is two to three times higher than those without the
disease [7]. However, for people without diabetes these estimates assume that diabetes confers the same
degree of risk in women as in men, which is unlikely because while non-diabetic women are relatively
protected from CVD, this advantage is lost in diabetes [8]. In the Framingham study, the incidence of
symptomatic heart failure was 2.4 times higher in men and 5.0 times higher in women with diabetes
as compared to non-diabetics [9]. This observation has been confirmed by other studies [10]. In the
HANAMI study, which included 764 subjects within the Mediterranean area, the rs146052672 variant
of High Mobility Group A 1 (HMGA 1) protein, associated with insulin resistance, type 2 diabetes
and the development of CVD was present in 50% female patients with diabetes who had an acute
myocardial infarction (AMI) compared to 24% of their male peers [11]. Furthermore, diabetic women
have a significantly higher mortality after myocardial infarction than diabetic men [12,13]. There is
a three times higher risk for fatal CAD in women with type 2 diabetes as compared to nondiabetic
women (95% confidence interval (CI), 1.9–4.8) [14]. Women with type 2 diabetes have a higher adjusted
hazard ratio (HR) of fatal CAD (HR = 14.74; 95% CI, 6.16–35.27) compared to type 2 diabetes men
(HR = 3.77; 95% CI, 2.52–5.65) [15]. In a meta-analysis of over 850,000 individuals the relative risk of
CVD was 44% greater in women with diabetes than in similarly affected men [16].
A gender difference was also observed in pre-clinical diabetic cardiomyopathy. In a series of
100 adults (44% females) with no previous evidence of heart disease, echocardiography showed the
presence of diabetic cardiomyopathy in 48% of patients, with the female gender among the strongest
predictors of cardiac remodeling [17]. In a series of 80 children and adolescents with well-controlled
type 1 diabetes, abnormalities in left ventricular dimensions and myocardial relaxation were reported,
with girls clearly more affected than boys [18]. Similarly, the relative risk of diabetes-related CAD
is substantially higher in women than in men, even after differences in other major cardiovascular
risk factors have been considered [16,19,20]. A recent systematic review and meta-analysis of all
prospective data available also estimate the relative effect of diabetes on the risk of stroke significantly
higher in women than in men, even after adjustment for differences in other major cardiovascular risk
factors [16,21,22]. These data add to existing evidence that men and women experience diabetes-related
diseases differently and suggest the need for further work to clarify the biological, behavioral, or
social mechanisms involved. In fact, the reason for this global “female disadvantage” in diabetes
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remains largely unknown. Sexual disparity in the management and treatment of cardiovascular risk
factors in individuals with diabetes, is possibly involved [23]. Data of nearly two million individuals
with diabetes in the United Kingdom have suggested that women with diabetes were less likely than
men with diabetes to receive treatment recommended by national guidelines and to meet treatment
targets [24]. These sex disparities in the treatment and management of individuals with diabetes alone,
however, may be too small to explain all the relative excess risk for CVD in women with diabetes.
Alternatively, as the detrimental effects of glucose have already occurred at glycemic levels below the
threshold for diagnosing diabetes, it could be that the transition from normoglycemia, to impaired
glucose tolerance and overt diabetes is more detrimental in women than in men [23]. As diabetes
can remain undetected for many years (about 183 million people with diabetes, 50% of all people
with diabetes, undiagnosed) [7], diagnosis is often made at an advanced stage, especially in women
due to disparities in diagnosis and treatment mentioned above, when major metabolic alterations
and vascular complications have already occurred in most patients [25]. Accumulating evidence
suggests that these adverse changes in metabolic and vascular risk factor profile in pre-diabetic
individuals are greater in women than in men [26–32]. These data may suggest that the diabetes-related
increased risk of cardiovascular disease in women may also be due to the combination of both a greater
deterioration in cardiovascular risk factor levels and a chronically elevated, but undiagnosed and
untreated, cardiovascular risk profile in the pre-diabetic state, beside any significant sex difference in
the effects and complications of diabetes itself [33,34].
3. Genetic, Epigenetic, and Hormonal Factors Involved in Sex-Specific Effects of Diabetes in CVD
Studies on animal models have helped to elucidate the potential pathogenic mechanisms of CVD,
but not to explain the interaction between sex/gender and diabetes, since most of the information
available derives from investigations performed on male rodents [35]. Thus, there is not yet sufficient
evidence on how gender differences modify the prevalence and incidence of CVD in the context of type
1 and or type diabetes. The mechanisms highlighted so far are essentially linked to the sex hormones
like estrogens, with clear influences on the differential regulation of the immune system in both sexes
(Table 1).
Table 1. Mechanisms and Risk Factors for Diabetes in Women.
Mechanisms and Environmental Factors Risk for Diabetes in Women
A lower proportions and numbers of CD8+ T cells [36] ↑
Viral infections [37] ↑
High expression of HLA-DR3 and DR4 alleles [37] ↑
Decreased DNA methylation of X-chromosome-related genes [37] ↑
Sex chromosome instability [37] ↑
Escape from X-chromosome inactivation [37] ↑
High expression of Receptors for estrogens in the heart and high
oxidative stress [38] ↑
Pathogens, xenobiotics and smoking [37] ↑
Different metabolism: High accumulation vs. low mobilization of
adipose tissue, and altered distribution of body fat associated with not
only sex hormones, but also with sex chromosome complement [39–43]
↑
Microbiome [37,44,45] ↑
Legend: ↑, increased.
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3.1. The Immune System Profile in Women
Women show a different profile of the immune system than men (the so-called immune
dimorphism) [36]. Specifically, women have lower proportions and numbers of CD8+ T cells,
higher proportions and numbers of CD4+ T cells, and higher CD4/CD8 ratios than men [36]. These sex
differences appear to be hormonally mediated since estrogen deficiency increases the proportion and
number of CD8+ T cells and decreases the CD4/CD8 ratio [36]. Thus, a lower number of CD8+ T cells
could contribute to the high incidence of chronic diseases in women, including metabolic disorders
and autoimmune diseases, as well as increased susceptibility to infections, particularly virus infections.
3.2. Genetics and Epigenetics
Genetic and epigenetic factors seem to be behind the aforementioned sexual dimorphism.
Women have higher expression of HLA-DR3 and DR4 alleles than men, decreased DNA methylation
of X-chromosome-related genes, sex chromosome instability, and escape from X-chromosome
inactivation [37].
3.3. Environmental Factors and Gut Microbiome
Environmental factors, such as pathogens, xenobiotics and smoking, also seem to favor the onset
and progression of metabolic and CVD diseases differently in both sexes, likely inducing a sustained
activation of immune/pro-inflammatory innate pathways than anti-inflammatory pathways, which is
facilitated by lower numbers of CD8+ T cells in women [37]. To this, we must also add the crucial
contribution of the gut microbiome, which differs between women and men, and seems to contribute
to the sex differences in diabetes and susceptibility to CVD [46,47]. This is consistent with the results
of studies reported in the literature in recent years, which emphasize the close relationship between
the gut microbiome and human health. Age and sex related perturbations in the gut microbiome
are linked to a wide range of conditions, including bowel disorders, autoimmune diseases, obesity,
and metabolic disorders [37]. The direct effect of the gut microbiota in obesity has been elegantly
highlighted in studies on mice, in which the gut microbiota from lean or obese mice were transplanted
into mice without germs. Mice with microbiota from diet-induced or genetically obese mice showed a
high weight compared to mice with microbiota from lean donors [44]. These results demonstrate that
the gut microbiome dramatically influences the host metabolism, including effects on the acquisition
and storage of energy, but also on the activity and phenotype profile of the immune system [37]. Thus,
alterations in the gut microbiome can impact the onset of diabetes and CVD in the two sexes differently
(Table 1).
3.4. Different Metabolism in Women: Correlation with the Different Asset of Sex Chromosome Genes
Dehghan and co-workers demonstrated the effect of inulin ingestion in controlling inflammation
and metabolic endotoxemia in women with diabetes [45] (Table 1). The effect of inulin underlines
the different metabolism of women, whose understanding is fundamental for the development of
appropriate measures for the prevention, diagnosis, and treatment of diseases. Specifically, women have
mechanisms that have evolved to favor the storage of adipose tissue. Thus, they tend to accumulate fat
mass and body weight and have an increased subcutaneous adipose tissue. In contrast, fat mobilization
is more efficient in males. In addition, women tend to have higher insulin sensitivity, and the sexes
differ in lipoprotein profiles. These differences are related to the levels of sex hormones, which are
reduced after menopause. Accordingly, investigations have demonstrated that post-menopausal
women have altered body fat distribution and increased incidence of CVD, hypertension, diabetes,
and other disorders [2,39,40]. These differences are not only related to sex hormones, but also to sex
chromosome complement. Thus, sex chromosome asset (or better sex chromosome genes asset) can
contribute to sex differences in metabolic traits [41–43] (Table 1).
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3.5. Estrogenes and Oxidative Stress
Estrogens also appear to affect the oxidative stress, which is considered a key mechanism in the
onset of CVD and diabetes (see Section 4.3 paragraph). Women before the menopause show lower
levels of oxidative stress than men, due to the antioxidant properties of estrogens, which modulate the
expression and levels of anti-oxidant enzymes, such as nicotinamide adenine dinucleotide phosphate
(NADPH)-oxidase (especially p47, Nox levels) and angiotensin II [38].
4. Cellular and Molecular Signaling Pathways Involved in Sex-Specific Effects of Diabetes
in CAD
A wide range of molecular mechanisms and inflammatory signaling pathways are associated
with the increased susceptibility of women to diabetes and CVD, such as CAD, as suggested by
the meta-inflammation hypothesis and widely summarized in the recent review of Aravindhan and
Madhumitha [48] (Figure 1). Specifically, women are characterized by a unique immune system
and metabolic profile, which is responsible for sustained activation of immune/pro-inflammatory
innate pathways and for the release of age-specific arterial secretory phenotype (AAASP) [49].
In turn, AAASP further exacerbates the systemic chronic low-grade of inflammation associated
with both onset of diabetes and related complications, such as CAD according to the concepts of
meta-inflammation [50,51]. Among the AAASP molecules, proinflammatory cytokines and chemokines,
and the monocyte chemoattractant protein (MCP-1), contribute to evocate a strong local inflammatory
state, and increase the low-grade systemic inflammation [50,51]. In addition, AAASP generate
dyslipidemia by increasing the accumulation of triglycerides-enriched lipoproteins directly (especially
VLDL) [52].
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Figure 1. Molecular pathways associated with diabetic macroangiopathy. The figure depicts some of the
key points discussed in the text on the role of advanced end products (AGE) products, innate immunity,
and reactive oxygen species generation in diabetic macroangiopathy. Abbreviations: RAGE, receptor
for advanced glycation end products; AGEs, advanced glycation endproducts; TLR, Toll-Like Receptor;
HMGB1, high mobility group box 1; IL, interleukin; TNF-α, tumor necrosis factor alpha; MCP-1,
Monocyte chemoattractant protein-1; VCAM-1 vascular cell adhesion molecule 1; ICAM-1, intercellular
adhesion molecule 1; ROS, reactive oxygen species; ox-LDL, oxidized low-density lipoprotein; NADPH,
nicotinamide adenine dinucleotide phosphate; NO, nitric oxyde; eNOS, endothelial nitric oxide synthase.
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The latter is also increased by both the excess of insulin and the insulin resistance, which also
contribute to the systemic accumulation of free fatty acids (FAs). Moreover, these mechanisms
associated with hyperglycemia determine the accumulation of toxic intermediates of lipid metabolism,
such as ceramide and diacylglycerol, and the accumulation of advanced end products (AGE). Toll-like
receptor (TLR)-2 and -4 [48], and receptors for advanced glycation end products (RAGEs), mediate
the biological effects described above by inducing independent responses or cross-mediated actions
via an active cross-talk between the two types of receptors. AGEs recruit inflammatory molecules by
interacting with RAGE, and elicit oxidative stress by increasing the production of reactive oxygen
species (ROS) and subsequently evoke the proliferation and fibrotic reaction. Thus, TLR-4 plays a
key role in the onset and progression of atherosclerosis, as well, as in CAD and other inflammatory
diseases, such as diabetes [53]. Moreover, it has recently been suggested that the crosstalk between
TLR-4 and dipeptidyl peptidase-4 (DPP-4)-incretin system is significantly associated with diabetes
and CAD. The whole action of all these signaling pathways, which is depicted in Figure 1, causes
changes in the coronary artery wall, including endothelial disruption, intima-media thickening, arterial
amyloidosis, fibrosis, elastin fracture, glycoxidative changes of the matrix, and the calcification [53–55].
4.1. The AGEs/RAGEs System in Diabetic Women
AGEs are formed during the Maillard process, a non enzymatic reaction between reducing sugars
and amino groups of proteins, lipids and nucleic acids [56]. The formation and accumulation of AGEs
occur at sustained rates in diabetic patients, and represent one of the most important mechanisms
of the pathophysiology of diabetic CAD. AGEs mediate their effects through the RAGE receptor, a
multi-ligand receptor and member of the super-family of immunoglobulin cell surface molecules,
expressed in vascular cells. They include NF-κB activation, the increase in the expression of cytokines
and adhesion molecules, the induction of oxidative stress, and the increase in the formation of cytosolic
reactive oxygen species (ROS) [56]. Furthermore, AGEs cause chemical and biophysical changes in
the collagen structure of the extracellular matrix, leading to functional alterations; i.e., thickening of
the basal membrane and increased resistance to proteolytic digestion [56]. In diabetic women, RAGE
is also induced by other ligands, such as high mobility group box 1 (HMGB1) that can interact with
both RAGE and TLR4 (and TLR2). This increases the activation of NF-κB and the expressions of
proinflammatory cytokines and pro-angiogenic molecules. AGEs have different intra- and extracellular
targets, so they can be considered as a “bridge” between intracellular and extracellular damage.
Moreover, whatever the level of hyperglycemia, AGE-related intracellular glycation of mitochondrial
respiratory chain proteins has been found to produce more abundant ROS, which further promotes
the formation of AGEs. The excessive formation of AGE leads to the thickening of macrovessel,
hypertension, endothelial dysfunction, loss of pericytes, decreased platelet survival and increased
platelet aggregation. All these abnormalities can promote the procoagulant state, resulting in ischemia
and induction of growth factors, with angiogenesis and neovascularization [56] (Figure 1).
4.2. The TLR-2 and -4 Signaling Pathways in Diabetic Women
The synergistic interaction between diabetes and CAD in women occurs through sterile
inflammation, also known as metabolic inflammation or meta-inflammation [48], by activating
TLR-2 and -4 signaling pathways [57]. This is supported by a recent study that showed increased
expression of the two TLR pathways in postmenopausal women with metabolic syndrome (MetS)
compared to women without MetS, accompanied by an increase in the levels of proinflammatory
molecules [58]. On the other hand, the TLR-2 and -4 signaling pathways are expressed in the gut cells,
β pancreatic cells and coronary artery cells [59]. In women, changes in the composition and levels
of the intestinal microbiota, with advanced age and as an effect of diet, can reduce the integrity of
the intestinal barrier and increase the loss of lipopolysaccharides and fatty acids, which can activate
TLR-2 and -4 and consequently can induce systemic inflammation. In fact, high levels of several
circulating inflammatory molecules are a common feature in the natural course of diabetes [59].
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Fatty acids can also trigger endoplasmic reticulum stress, which can be further stimulated by cross
talk with active TLR- 4 [57]. Furthermore, recent evidence also suggests that endogenous ligands
(i.e., endogenous damage-associated molecular patterns—DAMPs), such as saturated fatty acids and
necrotic cellular products, induce the activation of TLR-2 and 4 expressed on the β-cells and resident
macrophages, leading to insulin resistance, pancreatic β-cell dysfunction, and alteration of glucose
homeostasis [59]. Furthermore, the cooperation between RAGE and TLR2/and -4 has recently been
suggested to coordinate and regulate immune and inflammatory responses in diabetic patients [56]. The
synergistic activation of RAGE and TLR2/and-4 leads to the amplification of inflammatory responses.
RAGE and TLRs share several common ligands including HMGB [56]. RAGE also appears to interact
with TIRAP and MyD88, both of which are intracellular adapter proteins used by TLRs to activate
the downstream signaling pathway. The strong interaction between HMGB1-TLR-RAGE triggers the
activation of NF-κB and the consequent up-regulation of pro-inflammatory and pro-atherosclerotic
genes [56] (Figure 1). Thus, the synergistic action of two pathways, the AGEs/RAGEs axis and the
TLR-2 and -4 signaling pathways can play a major role in the atherosclerotic process in diabetic women.
The inhibition of these pathways could mitigate both the diabetic and atherosclerotic process and
reduce the risk of diabetic CAD. Numerous studies have shown that certain types of cardiovascular
drugs, such as statins, angiotensin II receptor antagonists and insulin sensitizers such as rosiglitazone
may exert anti-atherosclerosis effects, targeting these signaling pathways [53–55].
4.3. Oxidative Stress and Ox-LDL in Diabetic Women
Lower concentrations of very low density lipoproteins (VLDL) and low density lipoproteins (LDL)
in plasma in women compared to men are associated with accelerated (rather than reduced) VLDL and
LDL production [60]. In contrast, the secretion rate of VLDL apolipoprotein B-100 (VLDL particles) is
lower in women than in men. As a result, women produce less (on average) triglyceride-richer VLDL
than men [61]. There is no information regarding possible sex differences in cholesterol kinetics in the
various lipoprotein fractions in human subjects. However, animal studies support the important role of
endogenous sex hormones in mediating cholesterol metabolism in a sexually dimorphic manner [62].
In diabetic women, the production of accelerated LDL is accompanied by an increase in lipid
peroxidation and by the accumulation of oxidized low-density lipoprotein (ox-LDL) in the intima of the
arteries, which are among the main causes of endothelial dysfunction and early atherosclerosis [63–66].
The accumulation of ox-LDL in the intima and its subsequent uptake by the macrophages, lead to
the formation of foam cells through the interaction with lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1) receptor. LOX-1 is the most relevant receptor for ox-LDL in vascular endothelial cells,
macrophages and activated smooth muscle cells [65], and in diabetic and obese women its expression
is particularly high [67,68]. LOX-1 is a type II membrane protein with a C-type lectin-like structure
at the C-terminus, responsible for binding, uptake, and degradation of the ox-LDL. Its expression is
highly modulated by AGEs, cytokines, angiotensin (Ang) II, ox-LDL, shear stress and oxidative stress
by the activation of NF-κB [69–71]. The complete signaling pathway of ox-LDL/LOX-1 in diabetic
women is not yet clear. One of the hypothesized mechanisms is that the ox-LDL binding with LOX-1
activates the NADPH oxidase enzyme system, resulting in excessive superoxide generation [72]. The
scavenging of nitric oxide (NO) by superoxide can not only reduce the bioavailability of NO, but also
generate a more powerful oxidant such as peroxynitrite. Moreover, oxidative stress also downregulates
the endothelial nitric oxide synthase (eNOS), which becomes dysfunctional, promoting superoxide
formation (Figure 1). Other important mechanisms investigated are the activation of both the polyol
and protein kinase C pathways [73]. A recent study evaluated the levels of anti-ox LDL antibodies in
391 women of advanced age [71]. The population was classified as normal or with impaired glucose
tolerance, reduced fasting blood glucose or type 2 diabetes (T2DM), according to baseline glycemic
levels and after an oral glucose tolerance test. The same patients were studied again six years later.
Logistic regression analysis showed that the body mass index (p < 0.001) and the levels of anti-ox-LDL
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antibodies (p < 0.04) are among the main independent variables that predict the development of
T2DM [71].
5. Non-Invasive Assessment and Biomarkers of Coronary Artery Disease in Diabetic Women
One of the major challenges in the management of women with CAD, especially if diabetic, is that
they often present “atypical” symptoms. This is commonly associated with late or missed diagnosis [3].
Still worse, in the acute setting, women usually refer a less defined clinical presentation, including
dyspnea, stomach pain, nausea or fatigue, very often without classical chest pain [74]. This may
lead to a dangerous delay in the diagnosis [75]. In addition, as females were less represent than men
in large biomarker validation studies, standard diagnostic tests do not perform in women as well
as they do in men. In fact, according to a recent Scottish study, the usual diagnostic threshold for
standard troponin assays was too high for women, and the use of high-sensitivity troponin assays
could partially attenuate this shortcoming [76]. In this regard, the most appropriate way to improve
diagnostic efficacy in women should be to establish and validate an independent threshold. Women
often have a different response to drug treatments than men and this also applies to antiplatelet agents.
Low responsiveness in women can be even more dangerous than men, as they usually have a higher
residual platelet activity, both at baseline and under antiplatelet treatment [77]. This becomes a key
issue in diabetic women with CAD, especially in the context of acute coronary syndromes, also because
using aggregometry is less reliable in women than in men. Similar shortcomings are more evident
with the use of non-invasive assessment methods. In fact, despite the evidence that more than half
of the patients with CAD who die suddenly had no previous clinical evidence of CVD at all, the
establishment and robust validation of noninvasive methods to assess subclinical atherosclerosis has
always been a challenge [78]. Sudden cardiac death is an eminent exception to other cardiovascular
diseases, as it has a higher incidence in women compared to men [79]. As already described above
for chest pain, this is partly due to the wrong perception that women are “protected” from CVD
and partly to the often atypical clinical presentation of the disease in women. In fact, women with
Brugada Syndrome are more frequently asymptomatic and less frequently presenting a spontaneous
ECG pattern, compared to men [80]. Unfortunately, despite diabetic women having a high prevalence
of preclinical atherosclerosis, the utility of noninvasive screening in women is even more limited,
because of a lower sensibility of their men’s counterpart [81]. One common pitfall of current clinical
protocols for selection of subjects with suspected stable coronary artery disease is the frequent number
of coronary angiographies showing no critical coronary stenoses, thus exposing patients to unnecessary
procedural complications, which occurs more often in women than in men [82,83]. Interestingly, using
a recently developed novel application of flow-mediated dilation (FMD) that takes into account not
only the degree of dilation but the kinetics of its onset showed that the delayed onset of FMD after the
induction of ischemia was able to predict the presence of critical coronary stenoses, thus reducing the
number of unnecessary negative coronary angiographies in women [84] (Figure 2).
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because of a lower sensibility of their men’s counterpart [81]. One common pitfall of current clinical 
protocols for selection of subjects with suspected stable coronary artery disease is the frequent 
number of coronary angiographies showing no critical coronary stenoses, thus exposing patients to 
unnecessary procedural complications, which occurs more often in women than in men [82,83]. 
Interestingly, using a recently developed novel application of flow-mediated dilation (FMD) that 
takes into account not only the degree of dilation but the kinetics of its onset showed that the delayed 
onset of FMD after the induction of ischemia was able to predict the presence of critical coronary 
stenoses, thus reducing the number of unnecessary negative coronary angiographies in women [84] 
(Figure 2). 
 Figure 2. Noninvasive assessment of coronary artery disease in diabetic women. Although the risk of
heart disease in diabetic women may emerge before menopause, detection and evaluation of CAD are
difficult, due to the lower sensitivity and specificity of biomarker assays in women.
Results of the National Health and Nutrition Examination Survey (NHANES) and Atherosclerosis
Risk in Communities (ARIC) showed that the prevalence of an ankle brachial index (ABI) <0.90 in
women aged 40 to 59 years was about twice as high as for age-matched men, suggesting different ABI
thresholds for the diagnosis of peripheral artery disease (PAD) in men and women. In fact, the mean
ABI value in women was about 0.02 lower than in men. Interestingly, despite different thresholds were
used in the ARIC study for women (<0.90) and men (<0.08), a higher prevalence of PAD was found in
women [85]. Further studies have shown that diabetes is strongly associated with PAD in women. In
addition, women with an ABI <0.9 showed a greater extent of inducible myocardial ischemia than
those with an ABI ≥0.9, whereas the same was not found in men. This finding is consistent with the
more deleterious effect of diabetes on cardiac heart disease development observed in women [15].
Hence, ABI measurement could be useful in risk stratification of diabetic women to be selected for
coronary angiography [86]. On the contrary, stress testing studies performed with cardiac imaging
demonstrated less extensive ischemia in asymptomatic diabetic women compared with men [87].
However, despite smaller perfusion defects, prognosis of diabetic women is worse compared with
men [88]. The absence of coronary artery calcium (CAC) has a very high negative predictive value (99%)
for CAD in women above 50 years of age at intermediate cardiovascular risk [89]. Therefore, calcium
scoring with multi-slice dual energy computed-dual energy computed tomography (CT) represents a
very useful modality to rule out the presence of obstructive CAD, even though the radiation exposure
makes this technique less suitable in premenopausal women and for follow-up purposes. Prevalence
and severity of CAC in asymptomatic diabetics are similar to that of patients with established CAD
but without diabetes. Interestingly, men and women with diabetes have a similar extent of CAC,
confirming the clinical evidence that diabetes overrides the usual protection from CVD of women [90].
Positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) are the most
sensitive diagnostic methods to detect CAD without obstructive lesions or microvascular disease, both
conditions being more prevalent in women than in men [2]. PET might be very helpful to overcome
some of the difficulties in the diagnosis of CAD in diabetic patients and especially in women. In fact, it
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might be very useful in identifying individuals with at increased risk for vascular complications at an
early stage, even before they develop symptoms, as functional abnormalities are usually present way
earlier than morphological vessel alterations in CAD [91–94]. The reliable identification of subjects at
risk at an early stage would allow the initiation of risk-targeted cardiovascular prevention therapy,
with potential impact on the patient’s prognosis [91,95]. Furthermore, PET allows the identification of
global or regional circulatory dysfunction, including microvascular disease, through the assessment
of myocardial blood flow (MBF). Testing the changes in MBF in response to vasomotor stress (i.e.,
using the cold pressor test or pharmacological stimuli) might be exploited to identify early vascular
dysfunction as well as to monitor the effect of pharmacological treatments [91,96]. Moreover, the
development of advanced imaging modalities, that might be capable of identifying sites of vascular
inflammation and/or active atherothrombotic processes through noninvasive methods would be of
invaluable help to overcome the current problem that noninvasive biomarkers are less effective in
women than in men. Among the most promising techniques, the ultrasmall superparamagnetic iron
oxide (USPIO) was initially developed for magnetic resonance imaging (MRI), but the advent of the
higher resolution dual energy computed tomography (CT) allows to resolve USPIO in atherosclerotic
lesions, a reliable marker of activated macrophages [97]. Fusion imaging integrating information
from both PET and CT might be very useful in the noninvasive assessment of CAD in women. In
fact, multiple diagnostic studies demonstrated that the use of PET/CT scanners is associated with
an excellent diagnostic performance in CAD, being able to identify critical coronary stenoses (<70%
luminal narrowing) with 92% sensitivity and 90% specificity [98,99]. Combined CT and PET with
the radiotracer 18F sodium fluoride (18F-NaF) injection can identify coronary atherosclerotic plaques
that have ruptured or eroded. However, the processes behind 18F-NaF uptake in vulnerable plaques
remain unclear [100].
Very recently, the use of some nanobody-based radiotracers including vascular cell adhesion
molecule (VCAM)-1, macrophage mannose receptor (MMR) and LOX-1 through an integrative
multimodality positron emission tomography (PET)/MRI imaging protocol revealed very promising
for the noninvasive detection active atherosclerotic processes leading to disease progression or
instabilization [101]. This latter approach can be particularly useful for risk stratification in women to
overcome the above described limitations of current noninvasive markers, as it has been reported that
LOX-1-induced excessive superoxide generation is one factor explaining why high risk female subjects
escape from current risk stratification models [72].
Contrast-enhanced MRI might be helpful to identify an otherwise hidden anatomical substrate
for SCD risk in women with mitral valve prolapse. In fact, late enhancement was observed in 93%
of patients and—most importantly—it was identified within the same region where histopathology
substrate for SCD were found [102].
Intima-media thickness (IMT) increases with age, and is usually larger in men than women.
Among women with type-1 diabetes mellitus (T1DM), a significant association was also found between
common carotid IMT and CAD, measured by intravascular ultrasound [103]. Moreover, IMT was
strongly associated with body mass index (BMI), waist circumference, and total body fat in women
with T1DM. On the other hand, IMT above 0.9 mm or other signs of preclinical atherosclerosis were
associated with dysmetabolic status (fasting glucose, glycated haemoglobin, plasmatic atherogenic
index, TG, cholesterol) [104]. To this regard, it should be highlighted that women are exposed to a higher
cardiovascular risk after transition to menopause, as a consequence of multiple pro-atherothrombotic
changes [105]. Furthermore, women usually gain weight during the menopause, resulting in increased
prevalence of the metabolic syndrome [106]. The triglyceride-glucose index (TyG-Index) represents the
product of glycaemia and triglyceridaemia and is a simple and useful marker of insulin resistance [107].
A recent study demonstrated that normal-weight post-menopausal women with a TyG-Index crossing
the threshold of 8.0 have a significantly higher prevalence of subclinical atherosclerosis as their
counterparts with normal TyG index, which might therefore be used as an easy and low-cost screening
marker in the lean post-menopausal women [108].
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During the last years, initial evidence of specific genetic and epigenetic determinants of
cardiovascular risk has emerged. This might be helpful to improve cardiovascular risk stratification in
women [109]. For example, Ala16Val (rs4880), the most common gene variant of superoxide dismutase
(SOD) 2, a central element of physiological systems that protect cells against free radicals is associated
to a higher-than-expected cardiovascular risk in diabetic women, confirming that oxidative stress is
pivotal to undercover unapparent cardiovascular risk components [110]. Another example of genetic
variants associated with increased cardiovascular risk that is particularly useful in women is the −308
polymorphism of the promoter region of the TNF-α gene [111]. A recent genome-wide association
study (GWAS) conducted in more than 15,000 women was able to identify eight major pathways that
are modulated both by type 2 DM and CVD across different ethnic groups [112].
The clinical evidence and study results reported in this article are shown to highlight the most
relevant issues that are currently limiting the management of cardiovascular disease in diabetic women
and to raise the awareness on current discrepancies between men and women both on diagnosis and
treatment. However, since study designing was largely varying among the studies reported, their
results should be interpreted very cautiously. Findings of single studies are not directly comparable to
each other and no consequentiality should be assumed between them. In fact, despite adjustment for
relevant risk factors is often performed within single studies, it does not imply their generalizability.
Moreover, adjustment procedures do not completely exclude concealed influencing factors. Hence
all results that are not directing reflecting the main study outcome in randomized studies should be
considered hypothesis generating and not conclusive by any means.
6. Conclusions
Understanding sex differences and impact of diabetes on epidemiology, clinical presentation,
pathogenetic mechanisms and diagnosis of CAD and IHD is important because men and women
experience diabetes-related diseases differently, in terms of risk for coronary symptoms prognosis and
death. The reason for this global “female disadvantage” in diabetes remains largely unknown. Clearly,
the traditional view that the female “advantage” is only due to differences in the sex hormone milieu—in
particular, the availability of estrogens is not true, as many other factors can play a relevant role, such
as sexual dimorphism, sexual disparity in the management and treatment of cardiovascular risk factors
in individuals with diabetes, as well as genetic factors and sex chromosome genes asset. All factors
that make the difference in CAD and IHD in diabetic women compared to their male counterparts, in
terms of epidemiology, clinical presentation, pathogenesis and diagnosis, are summarized in Table 2.
Future studies are needed to determine how sex can modulate the effects of diabetes on cardiovascular
risk. Certainly, earlier interventions to better control risk factors for atherosclerotic disease in women
with diabetes can be done as it has potential to drastically reduce coronary mortality.
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Table 2. Sex differences and impact of diabetes on coronary atherosclerosis and ischemic heart disease.
Sex Differences Premenopausal
Women vs. Men
Effect of Diabetes Premenopausal
Women vs. Men
Cardiovascular risk ↓ ↑
Fatal CAD risk ↓ ↑
PAD risk ↑ ↑
Propensity to treat ↓ ↓
Delayed diagnosis ↑ ↑
CD4+/CD8+ T cells ratio ↑ ~
HLA-DR3 and DR4 alleles expression ↑ ~
DNA methylation of
X-chromosome-related genes ↓ ~
Sex chromosome instability ↓ ~
Escape from X-chromosome inactivation ↓ ~
Activation of immune/pro-inflammatory
innate pathways ↑ ↑
Different metabolism: High
accumulation vs. low mobilization of
adipose tissue
↑ ~
Oxidative stress ↓ ↑
Intestinal microbiome ↑ ↑
AGEs/RAGE activation ~ ↑
TLR-2 and -4 activation ~ ↑
LDL production ↑ ↑
LDL oxidation ↓ ↑
Ox-LDL/LOX-1 binding ↓ ↑
Foam cell formation ↓ ↑
Atypical angina ↑ ↑
Responsiveness to antiplatelet drugs ↓ ↓
Incidence of ABI <0.90 ↑ ↑
Ischemia area at cardiac stress imaging ↓ ↑
Prevalence and severity of CAC ~ ~
IMT ↓ ↑
Legend: ↓, reduced; ↑, increased; ~, no differences; CAD, coronary artery disease; PAD, peripheral artery disease;
AGEs, advanced glycation end-products; TLR, toll-like receptor; LDL low-density lipoproteins; Ox-LDL, oxidized
low-density lipoprotein; LOX, lectin-like oxidized low-density lipoprotein receptor; ABI, ankle brachial index; CAC,
coronary artery calcium; IMT, intima-media thickness.
Author Contributions: R.M. was involved in conception and manuscript design. R.M., C.R.B. and S.D.R. were
involved in drafting the manuscript. S.M. was involved in writing the paragraph oxidative stress and Ox-LDL in
diabetic women. R.D.C. and S.S. were involved in writing the paragraph “Noninvasive assessment and biomarkers
of coronary artery disease in diabetic women”. P.F., R.D.C. and R.M., C.R.B., G.S. and S.D.R. contributed in the
critical revision of the text of the manuscript. All authors participated in the study, and they read and approved
the final manuscript.
Funding: This work was supported by funds from the Italian Istituto Nazionale Ricerche Cardiovascolari (I.N.R.C.),
PRIN, and CARIPLO to R.M., and R.D.C.; the National Research, Development, and Innovation Office of Hungary
(OTKA KH_17 125570, NVKP 16-1-2016-0017 National Heart Program, and VEKOP-2.3.2-16-2016-00002) to P.F.;
the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within
the framework of the Therapeutic Development thematic programme of the Semmelweis University to P.F.; and
the European Cooperation in Science and Technology (COST EU-CARDIOPROTECTION CA16225; CARDIORNA
CA17129) to P.F.
Conflicts of Interest: P.F. is a founder and CEO of Pharmahungary Group, a group of R&D companies.
J. Clin. Med. 2019, 8, 98 13 of 18
References
1. European Heart Network. European Cardiovascular Disease Statistics 2017; European Heart Network: Brussels,
Belgium, 2017.
2. Maas, A.H.; Appelman, Y.E. Gender differences in coronary heart disease. Neth. Heart J. 2010, 18, 598–602.
[CrossRef]
3. Crilly, M.A.; Bundred, P.E.; Leckey, L.C.; Johnstone, F.C. Gender bias in the clinical management of women
with angina: Another look at the Yentl syndrome. J. Womens Health 2008, 17, 331–342. [CrossRef] [PubMed]
4. Arora, S.; Stouffer, G.A.; Kucharska-Newton, A.; Vaduganathan, M.; Qamar, A.; Matsushita, K.; Kolte, D.;
Reynolds, H.R.; Bangalore, S.; Rosamond, W.D.; et al. Fifteen-Year Trends in Management and Outcomes of
Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community
Surveillance Study, 2000–2014. J. Am. Heart Assoc. 2018, 7, e010203. [CrossRef]
5. White, U.A.; Tchoukalova, Y.D. Sex dimorphism and depot differences in adipose tissue function.
Biochim. Biophys. Acta 2014, 1842, 377–392. [CrossRef] [PubMed]
6. Vijay, V.; Han, T.; Moland, C.L.; Kwekel, J.C.; Fuscoe, J.C.; Desai, V.G. Sexual dimorphism in the expression of
mitochondria-related genes in rat heart at different ages. PLoS ONE 2015, 10, e0117047. [CrossRef] [PubMed]
7. International Diabetes Federation. Diabetes Atlas, 5th ed.; International Diabetes Federation: Brussels,
Belgium, 2011.
8. Masding, M.G.; Stears, A.J.; Burdge, G.C.; Wootton, S.A.; Sandeman, D.D. Premenopausal advantages in
postprandial lipid metabolism are lost in women with type 2 diabetes. Diabetes Care 2003, 26, 3243–3249.
[CrossRef]
9. Kannel, W.B.; Hjortland, M.; Castelli, W.P. Role of diabetes in congestive heart failure: The Framingham
study. Am. J. Cardiol. 1974, 34, 29–34. [CrossRef]
10. Ren, J.; Kelley, R.O. Cardiac health in women with metabolic syndrome: Clinical aspects and pathophysiology.
Obesity 2009, 17, 1114–1123. [CrossRef]
11. De Rosa, S.; Chiefari, E.; Salerno, N.; Ventura, V.; D’Ascoli, G.L.; Arcidiacono, B.; Ambrosio, G.; Bilotta, F.L.;
Torella, D.; Foti, D.; et al. HMGA1 is a novel candidate gene for myocardial infarction susceptibility.
Int. J. Cardiol. 2017, 227, 331–334. [CrossRef] [PubMed]
12. Barrett-Connor, E.L.; Cohn, B.A.; Wingard, D.L.; Edelstein, S.L. Why is diabetes mellitus a stronger risk
factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991, 265,
627–631. [CrossRef]
13. Barrett-Connor, E.; Bush, T.L. Estrogen and coronary heart disease in women. JAMA 1991, 265, 1861–1867.
[CrossRef]
14. Manson, J.E.; Colditz, G.A.; Stampfer, M.J.; Willett, W.C.; Krolewski, A.S.; Rosner, B.; Arky, R.A.; Speizer, F.E.;
Hennekens, C.H. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease
and stroke in women. Arch. Intern. Med. 1991, 151, 1141–1147. [CrossRef] [PubMed]
15. Juutilainen, A.; Kortelainen, S.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Gender difference in the
impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004, 27, 2898–2904. [CrossRef]
16. Huxley, R.; Barzi, F.; Woodward, M. Excess risk of fatal coronary heart disease associated with diabetes in
men and women: Meta-analysis of 37 prospective cohort studies. BMJ 2006, 332, 73–78. [CrossRef] [PubMed]
17. Kiencke, S.; Handschin, R.; von Dahlen, R.; Muser, J.; Brunner-Larocca, H.P.; Schumann, J.; Felix, B.;
Berneis, K.; Rickenbacher, P. Pre-clinical diabetic cardiomyopathy: Prevalence, screening, and outcome.
Eur. J. Heart Fail. 2010, 12, 951–957. [CrossRef]
18. Suys, B.E.; Katier, N.; Rooman, R.P.; Matthys, D.; Op De Beeck, L.; Du Caju, M.V.; De Wolf, D. Female children
and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic
cardiomyopathy. Diabetes Care 2004, 27, 1947–1953. [CrossRef] [PubMed]
19. Huxley, R.R.; Peters, S.A.; Mishra, G.D.; Woodward, M. Cardiovascular disease risk in type 1
diabetes—Authors’ reply. Lancet Diabetes Endocrinol. 2015, 3, 317. [CrossRef]
20. Huxley, R.R.; Peters, S.A.; Mishra, G.D.; Woodward, M. Risk of all-cause mortality and vascular events in
women versus men with type 1 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol.
2015, 3, 198–206. [CrossRef]
21. Peters, S.; Smit, E. Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer. Lancet Oncol. 2014, 15,
1289–1290. [CrossRef]
J. Clin. Med. 2019, 8, 98 14 of 18
22. Peters, S.A.; Huxley, R.R.; Woodward, M. Diabetes as a risk factor for stroke in women compared with
men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes.
Lancet 2014, 383, 1973–1980. [CrossRef]
23. Peters, S.A.; Huxley, R.R.; Sattar, N.; Woodward, M. Sex Differences in the Excess Risk of Cardiovascular
Diseases Associated with Type 2 Diabetes: Potential Explanations and Clinical Implications. Curr. Cardiovasc.
Risk Rep. 2015, 9, 36. [CrossRef] [PubMed]
24. National Diabetes Audit–2012–2013 Report 1: Care Processes and Treatment Targets, Health and Social Care
Information Centre 2014; NHS Digital: Leeds, UK, 2014.
25. Beckman, J.A.; Paneni, F.; Cosentino, F.; Creager, M.A. Diabetes and vascular disease: Pathophysiology,
clinical consequences, and medical therapy: Part II. Eur. Heart J. 2013, 34, 2444–2452. [CrossRef] [PubMed]
26. Evans, R.W.; Orchard, T.J. Oxidized lipids in insulin-dependent diabetes mellitus: A sex-diabetes interaction?
Metab. Clin. Exp. 1994, 43, 1196–1200. [CrossRef]
27. Howard, B.V.; Cowan, L.D.; Go, O.; Welty, T.K.; Robbins, D.C.; Lee, E.T. Adverse effects of diabetes on
multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care 1998, 21,
1258–1265. [CrossRef] [PubMed]
28. Mansfield, M.W.; Heywood, D.M.; Grant, P.J. Sex differences in coagulation and fibrinolysis in white subjects
with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 160–164. [CrossRef]
[PubMed]
29. Ossei-Gerning, N.; Wilson, I.J.; Grant, P.J. Sex differences in coagulation and fibrinolysis in subjects with
coronary artery disease. Thromb. Haemost. 1998, 79, 736–740. [CrossRef]
30. Steinberg, H.O.; Paradisi, G.; Cronin, J.; Crowde, K.; Hempfling, A.; Hook, G.; Baron, A.D. Type II diabetes
abrogates sex differences in endothelial function in premenopausal women. Circulation 2000, 101, 2040–2046.
[CrossRef] [PubMed]
31. Wannamethee, S.G.; Papacosta, O.; Lawlor, D.A.; Whincup, P.H.; Lowe, G.D.; Ebrahim, S.; Sattar, N. Do
women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes
than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia 2012, 55,
80–87. [CrossRef] [PubMed]
32. Garaulet, M.; Perex-Llamas, F.; Fuente, T.; Zamora, S.; Tebar, F.J. Anthropometric, computed tomography
and fat cell data in an obese population: Relationship with insulin, leptin, tumor necrosis factor-alpha, sex
hormone-binding globulin and sex hormones. Eur. J. Endocrinol. 2000, 143, 657–666. [CrossRef]
33. Donahue, R.P.; Rejman, K.; Rafalson, L.B.; Dmochowski, J.; Stranges, S.; Trevisan, M. Sex differences in
endothelial function markers before conversion to pre-diabetes: Does the clock start ticking earlier among
women? The Western New York Study. Diabetes Care 2007, 30, 354–359. [CrossRef]
34. Haffner, S.M.; Miettinen, H.; Stern, M.P. Relatively more atherogenic coronary heart disease risk factors in
prediabetic women than in prediabetic men. Diabetologia 1997, 40, 711–717. [CrossRef] [PubMed]
35. Bugger, H.; Abel, E.D. Rodent models of diabetic cardiomyopathy. Dis. Models Mech. 2009, 2, 454–466.
[CrossRef]
36. Bhatia, A.; Sekhon, H.K.; Kaur, G. Sex hormones and immune dimorphism. Sci. World J. 2014, 2014, 159150.
[CrossRef] [PubMed]
37. Balistreri, C.R.; Accardi, G.; Candore, G. Probiotics and Prebiotics: Health Promotion by Immune Modulation in
the Elderly; Academic Press: San Diego, CA, USA, 2013.
38. Kander, M.C.; Cui, Y.; Liu, Z. Gender difference in oxidative stress: A new look at the mechanisms for
cardiovascular diseases. J. Cell. Mol. Med. 2017, 21, 1024–1032. [CrossRef] [PubMed]
39. Garaulet, M.; Perez-Llamas, F.; Baraza, J.C.; Garcia-Prieto, M.D.; Fardy, P.S.; Tebar, F.J.; Zamora, S. Body
fat distribution in pre-and post-menopausal women: Metabolic and anthropometric variables. J. Nutr.
Health Aging 2002, 6, 123–126. [PubMed]
40. Lima, R.; Wofford, M.; Reckelhoff, J.F. Hypertension in postmenopausal women. Curr. Hypertens. Rep. 2012,
14, 254–260. [CrossRef]
41. Link, J.C.; Chen, X.; Arnold, A.P.; Reue, K. Metabolic impact of sex chromosomes. Adipocyte 2013, 2, 74–79.
[CrossRef]
42. Link, J.C.; Reue, K. Genetic Basis for Sex Differences in Obesity and Lipid Metabolism. Annu. Rev. Nutr.
2017, 37, 225–245. [CrossRef]
J. Clin. Med. 2019, 8, 98 15 of 18
43. Zore, T.; Palafox, M.; Reue, K. Sex differences in obesity, lipid metabolism, and inflammation-A role for the
sex chromosomes? Mol. Metab. 2018, 15, 35–44. [CrossRef] [PubMed]
44. Turnbaugh, P.J.; Backhed, F.; Fulton, L.; Gordon, J.I. Diet-induced obesity is linked to marked but reversible
alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3, 213–223. [CrossRef]
45. Dehghan, P.; Gargari, B.P.; Jafar-Abadi, M.A.; Aliasgharzadeh, A. Inulin controls inflammation and metabolic
endotoxemia in women with type 2 diabetes mellitus: A randomized-controlled clinical trial. Int. J. Food
Sci. Nutr. 2014, 65, 117–123. [CrossRef] [PubMed]
46. Sinha, T.; Vich Vila, A.; Garmaeva, S.; Jankipersadsing, S.A.; Imhann, F.; Collij, V.; Bonder, M.J.; Jiang, X.;
Gurry, T.; Alm, E.J.; et al. Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles.
Gut Microbes 2018, 29, 1–9. [CrossRef] [PubMed]
47. Vemuri, R.; Sylvia, K.E.; Klein, S.L.; Forster, S.C.; Plebanski, M.; Eri, R.; Flanagan, K.L. The microgenderome
revealed: Sex differences in bidirectional interactions between the microbiota, hormones, immunity and
disease susceptibility. Semin. Immunopathol. 2018. [CrossRef] [PubMed]
48. Aravindhan, V.; Madhumitha, H. Metainflammation in Diabetic Coronary Artery Disease: Emerging Role of
Innate and Adaptive Immune Responses. J. Diabetes Res. 2016, 2016, 6264149. [CrossRef] [PubMed]
49. Wang, M.; Monticone, R.E.; Lakatta, E.G. Proinflammation of aging central arteries: A mini-review.
Gerontology 2014, 60, 519–529. [CrossRef]
50. Lontchi-Yimagou, E.; Sobngwi, E.; Matsha, T.E.; Kengne, A.P. Diabetes mellitus and inflammation.
Curr. Diabetes Rep. 2013, 13, 435–444. [CrossRef] [PubMed]
51. Hotamisligil, G.S. Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542, 177–185.
[CrossRef]
52. Kim, S.H.; Lee, J.W.; Im, J.A.; Hwang, H.J. Monocyte chemoattractant protein-1 is related to metabolic
syndrome and homocysteine in subjects without clinically significant atherosclerotic cardiovascular disease.
Scand. J. Clin. Lab. Investig. 2011, 71, 1–6. [CrossRef]
53. Jia, S.J.; Niu, P.P.; Cong, J.Z.; Zhang, B.K.; Zhao, M. TLR4 signaling: A potential therapeutic target in ischemic
coronary artery disease. Int. Immunopharmacol. 2014, 23, 54–59. [CrossRef]
54. Balistreri, C.R.; Ruvolo, G.; Lio, D.; Madonna, R. Toll-like receptor-4 signaling pathway in aorta aging and
diseases: “its double nature”. J. Mol. Cell. Cardiol. 2017, 110, 38–53. [CrossRef]
55. Yamagishi, S.; Fukami, K.; Matsui, T. Crosstalk between advanced glycation end products (AGEs)-receptor
RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc. Diabetol.
2015, 14, 2. [CrossRef] [PubMed]
56. Madonna, R.; Balistreri, C.R.; Geng, Y.J.; De Caterina, R. Diabetic microangiopathy: Pathogenetic insights
and novel therapeutic approaches. Vasc. Pharmacol. 2017, 90, 1–7. [CrossRef] [PubMed]
57. Velloso, L.A.; Folli, F.; Saad, M.J. TLR4 at the Crossroads of Nutrients, Gut Microbiota, and Metabolic
Inflammation. Endocr. Rev. 2015, 36, 245–271. [CrossRef] [PubMed]
58. Orsatti, C.L.; Petri Nahas, E.A.; Nahas-Neto, J.; Orsatti, F.L.; Giorgi, V.I.; Witkin, S.S. Evaluation of Toll-Like
receptor 2 and 4 RNA expression and the cytokine profile in postmenopausal women with metabolic
syndrome. PLoS ONE 2014, 9, e109259. [CrossRef]
59. Balistreri, C.R.; Bonfigli, A.R.; Boemi, M.; Olivieri, F.; Ceriello, A.; Genovese, S.; Franceschi, C.; Spazzafumo, L.;
Fabietti, P.; Candore, G.; et al. Evidences of +896 A/G TLR4 polymorphism as an indicative of prevalence of
complications in T2DM patients. Med. Inflamm. 2014, 2014, 973139. [CrossRef] [PubMed]
60. Matthan, N.R.; Jalbert, S.M.; Barrett, P.H.; Dolnikowski, G.G.; Schaefer, E.J.; Lichtenstein, A.H. Gender-specific
differences in the kinetics of nonfasting TRL, IDL, and LDL apolipoprotein B-100 in men and premenopausal
women. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1838–1843. [CrossRef]
61. Magkos, F.; Patterson, B.W.; Mohammed, B.S.; Klein, S.; Mittendorfer, B. Women produce fewer but
triglyceride-richer very low-density lipoproteins than men. J. Clin. Endocrinol. Metab. 2007, 92, 1311–1318.
[CrossRef]
62. Hewitt, K.N.; Boon, W.C.; Murata, Y.; Jones, M.E.; Simpson, E.R. The aromatase knockout mouse presents with
a sexually dimorphic disruption to cholesterol homeostasis. Endocrinology 2003, 144, 3895–3903. [CrossRef]
63. Sakurai, K.; Sawamura, T. Stress and vascular responses: Endothelial dysfunction via lectin-like oxidized
low-density lipoprotein receptor-1: Close relationships with oxidative stress. J. Pharmacol. Sci. 2003, 91,
182–186. [CrossRef]
J. Clin. Med. 2019, 8, 98 16 of 18
64. Mehta, J.L.; Chen, J.; Hermonat, P.L.; Romeo, F.; Novelli, G. Lectin-like, oxidized low-density lipoprotein
receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders.
Cardiovasc. Res. 2006, 69, 36–45. [CrossRef]
65. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813–820.
[CrossRef] [PubMed]
66. Kork, F.; Jankowski, V.; Just, A.R.; Pfeilschifter, J.; Tepel, M.; Zidek, W.; Jankowski, J. Oxidized low-density
lipoprotein in postmenopausal women. J. Hypertens. 2014, 32, 1444–1449. [CrossRef] [PubMed]
67. Brinkley, T.E.; Kume, N.; Mitsuoka, H.; Phares, D.A.; Hagberg, J.M. Elevated soluble lectin-like oxidized
LDL receptor-1 (sLOX-1) levels in obese postmenopausal women. Obesity 2008, 16, 1454–1456. [CrossRef]
[PubMed]
68. Bukowska, A.; Spiller, L.; Wolke, C.; Lendeckel, U.; Weinert, S.; Hoffmann, J.; Bornfleth, P.; Kutschka, I.;
Gardemann, A.; Isermann, B.; et al. Protective regulation of the ACE2/ACE gene expression by estrogen in
human atrial tissue from elderly men. Exp. Biol. Med. 2017, 242, 1412–1423. [CrossRef]
69. Kume, N.; Murase, T.; Moriwaki, H.; Aoyama, T.; Sawamura, T.; Masaki, T.; Kita, T. Inducible expression of
lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ. Res. 1998, 83, 322–327. [CrossRef]
[PubMed]
70. Chen, M.; Nagase, M.; Fujita, T.; Narumiya, S.; Masaki, T.; Sawamura, T. Diabetes enhances lectin-like
oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: Possible role of LOX-1 ligand and
AGE. Biochem. Biophys. Res. Commun. 2001, 287, 962–968. [CrossRef]
71. Garrido-Sanchez, L.; Cardona, F.; Garcia-Fuentes, E.; Rojo-Martinez, G.; Gomez-Zumaquero, J.M.; Picon, M.J.;
Soriguer, F.; Tinahones, F.J. Anti-oxidized low-density lipoprotein antibody levels are associated with the
development of type 2 diabetes mellitus. Eur. J. Clin. Investig. 2008, 38, 615–621. [CrossRef]
72. Cominacini, L.; Rigoni, A.; Pasini, A.F.; Garbin, U.; Davoli, A.; Campagnola, M.; Pastorino, A.M.; Lo Cascio, V.;
Sawamura, T. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the
intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide.
J. Biol. Chem. 2001, 276, 13750–13755. [CrossRef]
73. Bertoluci, M.C.; Ce, G.V.; da Silva, A.M.; Wainstein, M.V.; Boff, W.; Punales, M. Endothelial dysfunction as a
predictor of cardiovascular disease in type 1 diabetes. World J. Diabetes 2015, 6, 679–692. [CrossRef]
74. Meischke, H.; Larsen, M.P.; Eisenberg, M.S. Gender differences in reported symptoms for acute myocardial
infarction: Impact on prehospital delay time interval. Am. J. Emerg. Med. 1998, 16, 363–366. [CrossRef]
75. Khan, N.A.; Daskalopoulou, S.S.; Karp, I.; Eisenberg, M.J.; Pelletier, R.; Tsadok, M.A.; Dasgupta, K.;
Norris, C.M.; Pilote, L.; Genesis Praxy Team. Sex differences in acute coronary syndrome symptom
presentation in young patients. JAMA Intern. Med. 2013, 173, 1863–1871. [PubMed]
76. Shah, A.S.; Griffiths, M.; Lee, K.K.; McAllister, D.A.; Hunter, A.L.; Ferry, A.V.; Cruikshank, A.; Reid, A.;
Stoddart, M.; Strachan, F.; et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial
infarction in women: Prospective cohort study. BMJ 2015, 350, g7873. [CrossRef] [PubMed]
77. Levin, R.I. The puzzle of aspirin and sex. N. Engl. J. Med. 2005, 352, 1366–1368. [CrossRef] [PubMed]
78. Kuller, L.; Borhani, N.; Furberg, C.; Gardin, J.; Manolio, T.; O’Leary, D.; Psaty, B.; Robbins, J. Prevalence of
subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular
Health Study. Am. J. Epidemiol. 1994, 139, 1164–1179. [CrossRef]
79. Karam, N.; Marijon, E.; Bougouin, W.; Spaulding, C.; Jouven, X. [Sudden cardiac death: Are women
different?]. Annales de Cardiologie et D’angeiologie. 2016, 65, 390–394. [CrossRef]
80. Berthome, P.; Tixier, R.; Briand, J.; Geoffroy, O.; Babuty, D.; Mansourati, J.; Jesel, L.; Dupuis, J.M.; Bru, P.;
Kyndt, F.; et al. Clinical presentation and follow-up of women affected by Brugada syndrome. Heart Rhythm
2018. [CrossRef] [PubMed]
81. Catalan, M.; Herreras, Z.; Pinyol, M.; Sala-Vila, A.; Amor, A.J.; de Groot, E.; Gilabert, R.; Ros, E.; Ortega, E.
Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. Nutrition,
metabolism, and cardiovascular diseases. NMCD 2015, 25, 742–748.
82. Reynolds, H.R.; Hausvater, A.; Carney, K. Test Selection for Women with Suspected Stable Ischemic Heart
Disease. J. Womens Health 2018, 27, 867–874. [CrossRef] [PubMed]
83. Pathak, L.A.; Shirodkar, S.; Ruparelia, R.; Rajebahadur, J. Coronary artery disease in women. Indian Heart J.
2017, 69, 532–538. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 98 17 of 18
84. Irace, C.; De Rosa, S.; Tripolino, C.; Ambrosio, G.; Covello, C.; Abramo, E.; Carallo, C.; Mongiardo, A.;
Spaccarotella, C.; Torella, D.; et al. Delayed flow-mediated vasodilation and critical coronary stenosis.
J. Investig. Med. 2018, 66, 1–7. [CrossRef] [PubMed]
85. Aboyans, V.; Criqui, M.H.; McClelland, R.L.; Allison, M.A.; McDermott, M.M.; Goff, D.C., Jr.; Manolio, T.A.
Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: The Multi-Ethnic Study
of Atherosclerosis (MESA). J. Vasc. Surg. 2007, 45, 319–327. [CrossRef] [PubMed]
86. Igarashi, Y.; Chikamori, T.; Hida, S.; Tanaka, H.; Shiba, C.; Usui, Y.; Hatano, T.; Yamashina, A. Importance
of the ankle-brachial pressure index in the diagnosis of coronary artery disease in women with diabetes
without anginal pain. Circ. J. 2011, 75, 2206–2212. [CrossRef] [PubMed]
87. Raggi, P.; Gongora, M.C.; Gopal, A.; Callister, T.Q.; Budoff, M.; Shaw, L.J. Coronary artery calcium to predict
all-cause mortality in elderly men and women. J. Am. Coll. Cardiol. 2008, 52, 17–23. [CrossRef]
88. Wackers, F.J.; Young, L.H.; Inzucchi, S.E.; Chyun, D.A.; Davey, J.A.; Barrett, E.J.; Taillefer, R.; Wittlin, S.D.;
Heller, G.V.; Filipchuk, N.; et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects:
The DIAD study. Diabetes Care 2004, 27, 1954–1961. [CrossRef] [PubMed]
89. Berman, D.S.; Kang, X.; Hayes, S.W.; Friedman, J.D.; Cohen, I.; Abidov, A.; Shaw, L.J.; Amanullah, A.M.;
Germano, G.; Hachamovitch, R. Adenosine myocardial perfusion single-photon emission computed
tomography in women compared with men. Impact of diabetes mellitus on incremental prognostic
value and effect on patient management. J. Am. Coll. Cardiol. 2003, 41, 1125–1133. [CrossRef]
90. Mielke, C.H.; Shields, J.P.; Broemeling, L.D. Coronary artery calcium, coronary artery disease, and diabetes.
Diabetes Res. Clin. Pract. 2001, 53, 55–61. [CrossRef]
91. Schindler, T.H.; Zhang, X.L.; Vincenti, G.; Mhiri, L.; Lerch, R.; Schelbert, H.R. Role of PET in the evaluation
and understanding of coronary physiology. J. Nucl. Cardiol. 2007, 14, 589–603. [CrossRef]
92. Camici, P.G.; Crea, F. Coronary microvascular dysfunction. N. Engl. J. Med. 2007, 356, 830–840. [CrossRef]
93. Bengel, F.M.; Higuchi, T.; Javadi, M.S.; Lautamaki, R. Cardiac positron emission tomography. J. Am.
Coll. Cardiol. 2009, 54, 1–15. [CrossRef]
94. Camici, P.G.; Rimoldi, O.E. The clinical value of myocardial blood flow measurement. J. Nucl. Med. 2009, 50,
1076–1087. [CrossRef]
95. Ganz, P.; Vita, J.A. Testing endothelial vasomotor function: Nitric oxide, a multipotent molecule. Circulation
2003, 108, 2049–2053. [CrossRef] [PubMed]
96. Naya, M.; Tsukamoto, T.; Morita, K.; Katoh, C.; Furumoto, T.; Fujii, S.; Tamaki, N.; Tsutsui, H. Olmesartan,
but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J. Am.
Coll. Cardiol. 2007, 50, 1144–1149. [CrossRef]
97. Sato, H.; Fujimoto, S.; Kogure, Y.; Daida, H. Feasibility of Macrophage Plaque Imaging Using Novel Ultrasmall
Superparamagnetic Iron Oxide in Dual Energy CT. Eur. J. Radiol. Open 2018, 5, 87–91. [CrossRef]
98. Sampson, U.K.; Dorbala, S.; Limaye, A.; Kwong, R.; Di Carli, M.F. Diagnostic accuracy of rubidium-82
myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the
detection of coronary artery disease. J. Am. Coll. Cardiol. 2007, 49, 1052–1058. [CrossRef] [PubMed]
99. Bateman, T.M.; Heller, G.V.; McGhie, A.I.; Friedman, J.D.; Case, J.A.; Bryngelson, J.R.; Hertenstein, G.K.;
Moutray, K.L.; Reid, K.; Cullom, S.J. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion
PET: Comparison with ECG-gated Tc-99m sestamibi SPECT. J. Nucl. Cardiol. 2006, 13, 24–33. [CrossRef]
[PubMed]
100. Marchesseau, S.; Seneviratna, A.; Sjoholm, A.T.; Qin, D.L.; Ho, J.X.M.; Hausenloy, D.J.; Townsend, D.W.;
Richards, A.M.; Totman, J.J.; Chan, M.Y.Y.; et al. Hybrid PET/CT and PET/MRI imaging of vulnerable
coronary plaque and myocardial scar tissue in acute myocardial infarction. J. Nucl. Cardiol. 2018, 25,
2001–2011. [CrossRef]
101. Senders, M.L.; Hernot, S.; Carlucci, G.; van de Voort, J.C.; Fay, F.; Calcagno, C.; Tang, J.; Alaarg, A.; Zhao, Y.;
Ishino, S.; et al. Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC
Cardiovasc. Imaging 2018. [CrossRef] [PubMed]
102. Basso, C.; Perazzolo Marra, M.; Rizzo, S.; De Lazzari, M.; Giorgi, B.; Cipriani, A.; Frigo, A.C.; Rigato, I.;
Migliore, F.; Pilichou, K.; et al. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death. Circulation
2015, 132, 556–566. [CrossRef]
J. Clin. Med. 2019, 8, 98 18 of 18
103. Larsen, J.R.; Brekke, M.; Bergengen, L.; Sandvik, L.; Arnesen, H.; Hanssen, K.F.; Dahl-Jorgensen, K. Mean
HbA1c over 18 years predicts carotid intima media thickness in women with type 1 diabetes. Diabetologia
2005, 48, 776–779. [CrossRef]
104. Pithova, P.; Stechova, K.; Pitha, J.; Lanska, V.; Kvapil, M. Determinants of preclinical atherosclerosis are
different in type 1 and type 2 diabetic women. Physiol. Res. 2016, 65, 219–228.
105. Woodard, G.A.; Brooks, M.M.; Barinas-Mitchell, E.; Mackey, R.H.; Matthews, K.A.; Sutton-Tyrrell, K.
Lipids, menopause, and early atherosclerosis in Study of Women’s Health Across the Nation Heart women.
Menopause 2011, 18, 376–384. [CrossRef]
106. Polotsky, H.N.; Polotsky, A.J. Metabolic implications of menopause. Semin. Reprod. Med. 2010, 28, 426–434.
[CrossRef] [PubMed]
107. Sanchez-Inigo, L.; Navarro-Gonzalez, D.; Fernandez-Montero, A.; Pastrana-Delgado, J.; Martinez, J.A. The
TyG index may predict the development of cardiovascular events. Eur. J. Clin. Investig. 2016, 46, 189–197.
[CrossRef] [PubMed]
108. Lambrinoudaki, I.; Kazani, M.V.; Armeni, E.; Georgiopoulos, G.; Tampakis, K.; Rizos, D.; Augoulea, A.;
Kaparos, G.; Alexandrou, A.; Stamatelopoulos, K. The TyG Index as a Marker of Subclinical Atherosclerosis
and Arterial Stiffness in Lean and Overweight Postmenopausal Women. Heart Lung Circ. 2018, 27, 716–724.
[CrossRef] [PubMed]
109. De Rosa, S.; Arcidiacono, B.; Chiefari, E.; Brunetti, A.; Indolfi, C.; Foti, D.P. Type 2 Diabetes Mellitus and
Cardiovascular Disease: Genetic and Epigenetic Links. Front. Endocrinol. 2018, 9, 2. [CrossRef] [PubMed]
110. Jones, D.A.; Prior, S.L.; Tang, T.S.; Bain, S.C.; Hurel, S.J.; Humphries, S.E.; Stephens, J.W. Association between
the rs4880 superoxide dismutase 2 (C>T) gene variant and coronary heart disease in diabetes mellitus.
Diabetes Res. Clin. Pract. 2010, 90, 196–201. [CrossRef] [PubMed]
111. Vendrell, J.; Fernandez-Real, J.M.; Gutierrez, C.; Zamora, A.; Simon, I.; Bardaji, A.; Ricart, W.; Richart, C. A
polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary
heart disease in type 2 diabetic patients. Atherosclerosis 2003, 167, 257–264. [CrossRef]
112. Chan, K.H.; Huang, Y.T.; Meng, Q.; Wu, C.; Reiner, A.; Sobel, E.M.; Tinker, L.; Lusis, A.J.; Yang, X.; Liu, S.
Shared molecular pathways and gene networks for cardiovascular disease and type 2 diabetes mellitus in
women across diverse ethnicities. Circulation. Cardiovasc. Genet. 2014, 7, 911–919. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
